Bavarian Nordic appoints board observer intended to take chairmanship

According to plans, GSK veteran Luc Debruyne will begin as an observer to the board of the Danish drugmaker before being nominated as chairman in 2023.

Photo: Lukas Barth/Reuters/Ritzau Scanpix

On Tuesday, Bavarian Nordic announced in a press release the appointment of Luc Debruyne as observer to the board of directors with the intention for him to succeed Gerard van Odijk as chairman next year.

Debruyne spent six years as president for Global Vaccines during his 27-year long stay at GSK.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs